NCT05210868进行中（未招募）1 期
A Phase I/II Open-Label, Single-Arm, Multicenter Clinical Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 184
- 试验地点
- 1
- 主要终点
- Dose-limiting toxicities (DLT)
研究概览
简要总结
A Phase I/II Open-Label, Single-Arm, Multicenter Clinical Study of CM355 in Patients With R/R B-NHL
详细描述
This is a phase I/II open-label, single-arm, multicenter study in China to evaluate the safety, tolerability, and efficacy of CM355 in patients with R/R B-NHL. In the study, patients will not be screened for CD20 expression, but they must have a diagnosis of B-NHL that is expected to express CD20. After enrollment, tumor samples will be collected for retrospective analysis of CD20 expression
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥ 18 years old.
- •Eastern Cooperative Oncology Group (ECOG, see Appendix 3) PS score of 0-
- •Histopathologically confirmed relapsed or refractory B-cell NHL has been confirmed or anticipated to express CD20 in lymphoma lesions.
- •According to Lugano criteria, imaging evaluation shows at least one bidimensionally measurable lesion.
- •The level of organ function of patients must In line with the testing standard of the clinical trial center prior to the first dose of the investigational drug
- •Expected survival ≥ 3 months.
- •All toxicities caused by prior anticancer therapy must have recovered to grade ≤ 1 (based on CTCAE v5.0) except alopecia and fatigue.
- •Female patients with childbearing potential should have a negative blood pregnancy test result within 7 days prior to the first dose.
- •Female patients with childbearing potential or male patients and their partners must agree to take effective contraceptive measures from the signing of the ICF to at least 6 months after the last dose of investigational drug.
- •Female patients cannot breastfeed or plan to become pregnant during the study until at least 6 months after the last dose of investigational drug.
- •The patient voluntarily joined the study and signed the ICF.
排除标准
- •Active or past central nervous system (CNS) lymphoma.
- •Other active malignancies occurring within 5 years prior to the first dose of investigational drug, with the exception of radically treated local curable cancers.
- •The patient has a disease or medical history that needs to be excluded as specified in the Clinical Trial Protocol.
- •Any active infection requiring systemic therapy via intravenous infusion within 14 days prior to the first dose of investigational drug.
- •According to the trial scheme, patients infected with hepatitis B virus, hepatitis C virus, HIV, EBV, CMV, syphilis, or patients with active pulmonary tuberculosis or history of pulmonary tuberculosis infection are not suitable to participate in the study.
- •Any severe or uncontrolled systemic disease.
- •History of severe allergic reactions (CTCAE v5.0 classification is greater than 3 grades) to humanized monoclonal antibodies, or known hypersensitivity to any component of CM
- •Any mental or cognitive disorder that may limit the patient's understanding and execution of the ICF and compliance with the study.
- •Medication history and surgical history:
- •Having received allogeneic hematopoietic stem cell transplantation or received auto-HSCT within 100 days prior to the first dose.
- •Active bleeding within 2 months prior to screening, or receiving anticoagulants, or other bleeding symptoms requiring medical intervention.
- •Having undergone major surgery within 28 days prior to the first dose, or minor surgery within 2 weeks prior to the first dose; invasive examinations for the purpose of diagnosis are not considered as surgery; except for the insertion of vascular access device.
- •Patients who experienced grade ≥ 3, severe or life-threatening immune-related adverse events or grade 1-2 immune-related adverse events that did not return to baseline levels after treatment discontinuation in a previous immunotherapy.
- •Patients who have received any other investigational anti-cancer drug therapy within 28 days prior to the first dose.
- •Inoculation of live attenuated vaccines within 28 days prior to the first dose, or anticipation that live attenuated vaccines will be required during the study.
- •Patients who have received any drugs therapy that need to be excluded from the Clinical Trial Protocol within a certain period of time for the first administration.
- •Prior participation in other clinical trials within 28 days prior to the first dose of the investigational drug, or planning to participate in this study and other clinical trials at the same time.
- •Known alcoholism or drug abuse history.
- •Other conditions determined by the investigator that render patients unsuitable for participation in this study.
研究组 & 干预措施
CM355
Experimental
- Dose Escalation Phase CM355
- Dose Expansion Phase CM355
干预措施: CM355 (Drug)
结局指标
主要结局
Dose-limiting toxicities (DLT)
时间窗: Up to 2 year
Incidence, nature, and severity of dose-limiting toxicities.
Recommended phase II dose (RP2D) and/or (maximum tolerated dose) MTD
时间窗: Up to 2 year
To determine the recommended phase II dose (RP2D) and/or the maximum tolerated dose (MTD) of CM355 in patients with R/R B-NHL.
The safety and tolerability of CM355
时间窗: through study completion，an average of 5 year
Incidence, nature, and severity of adverse events (AEs) as judged according to NCI-CTCAE v5.0.
Objective response rate（ORR）
时间窗: through study completion，an average of 5 year
Objective response rate (ORR) as assessed by independent review committee (IRC)
次要结局
- Peak Plasma Concentration (Cmax)(Every cycle (21 days), until the end of treatment)
- Objective response rate (ORR)(through study completion，an average of 5 year)
- Area under the plasma concentration versus time curve (AUC)(Every cycle (21 days), until the end of treatment)
- Peak time(Every cycle (21 days), until the end of treatment)
- overall survival (OS)(through study completion，an average of 5 year)
- Clearanc (CL)(Every cycle (21 days), until the end of treatment)
- Progression-Free-Survival (PFS)(through study completion，an average of 5 year)
- T1/2(Every cycle (21 days), until the end of treatment)
- Anti-CM355 antibodies (ADAs)(Every cycle (21 days), until the end of treatment)
- Duration of response (DOR)(through study completion，an average of 5 year)
- Complete response rate (CRR)(through study completion，an average of 5 year)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
MB-105 in Patients With CD5 Positive T-cell LymphomaLymphoma, T-CellNCT06534060March Biosciences Inc46
终止
2 期
Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic PhaseChronic Myeloid Leukemia in Chronic PhaseNCT00451035Novartis Pharmaceuticals29
撤回
1 期
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell DiseasesRelapsed or Refractory Multiple MyelomaOther Plasma Cell DiseasesNCT05647512LaNova Medicines Limited
终止
2 期
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast PhaseLeukemia, Myeloid, ChronicNCT00449761Novartis Pharmaceuticals27
已完成
2 期
Leronlimab (PRO 140) in Patients With Nonalcoholic SteatohepatitisNonalcoholic Steatohepatitis (NASH)NCT04521114CytoDyn, Inc.87